Helsinn Healthcare S.A.

Helsinn adopts a Multi-project Integrated Licensing strategy which focuses on taking valuable pharmaceutical compounds from an early clinical phase to a secure international market position and providing its partners with continuous scientific and market value. Helsinn has proven expertise in three principle therapeutic areas: Oncology and Supportive Care (Palonosetron: Aloxi®, Onicit®, Gelclair®, Netupitant) , Anti-inflammatory (Nimesulide: Aulin®, Ainex®, Donulide®, Edrigyl®, Eskaflam®, Heugan®, Mesulid®, Nexen®, Nimed®,Nimedex®, Nisulid®, Scaflam®, Scaflan®. Oxaprozin: Dayrun®, Danoprox®, Duraprox®, Flusyd®, Walix®) and Gastrointestinal (Klean-Prep®).